ReviewPharmacoEconomics1999
Health economics in HIV disease. A review of the European literature.
Review in PharmacoEconomics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Economic evaluation studies in the field of HIV/AIDS: bibliometric analysis on research development and scopes (GAPBMC health services research · 2019Article
- HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.PLoS medicine · 2012Article
- Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.PharmacoEconomics · 2010Article
- Use and cost of antiretrovirals in France 1995-2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database.PharmacoEconomics · 2004Article
- The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
- Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.PharmacoEconomics · 2001Article
- Efavirenz: a pharmacoeconomic review of its use in HIV infection.PharmacoEconomics · 2001Review
- The cost of HIV treatment and care. A global review.PharmacoEconomics · 2001Review
- Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.Drugs · 2000Review
- Comparison of the quality of life of comorbid and non-comorbid people living with HIV/AIDS in a Nigerian secondary healthcare facility.Journal of multimorbidity and comorbidityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the economic consequences of, differing models of care are poorly documented or understood. Most available economic and clinical data, especially data documenting post-therapy outcomes, are from small, short term studies. This has led to the use of modelling to estimate which determinants can improve the quality and cost effectiveness of HIV care in the future. Although the attempt to provide what is currently perceived to be the standard of care is stretching many healthcare budgets, it is an anachronism that there are few studies of health economics in HIV disease. Most published data relate only to North America, and there remains a paucity of European studies. This paper provides a review of the available data from Europe and attempts to highlight the trends that have taken place to date.
Indexed as
Identifiers
10537438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.